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Abstract 
Background: HIV-1 replication kinetics inherently depends on the availability of cellular dNTPs for viral DNA synthe-
sis. In activated CD4+ T cells and other rapidly dividing cells, the concentrations of dNTPs are high and HIV-1 reverse 
transcription occurs in an efficient manner. In contrast, nondividing cells such as macrophages have lower dNTP 
pools, which restricts efficient reverse transcription. Clofarabine is an FDA approved ribonucleotide reductase inhibi-
tor, which has shown potent antiretroviral activity in transformed cell lines. Here, we explore the potency, toxicity and 
mechanism of action of clofarabine in the human primary HIV-1 target cells: activated CD4+ T cells and macrophages.
Results: Clofarabine is a potent HIV-1 inhibitor in both activated CD4+ T cells and macrophages. Due to its minimal 
toxicity in macrophages, clofarabine displays a selectivity index over 300 in this nondividing cell type. The anti-HIV-1 
activity of clofarabine correlated with a significant decrease in both cellular dNTP levels and viral DNA synthesis. Addi-
tionally, we observed that clofarabine triphosphate was directly incorporated into DNA by HIV-1 reverse transcriptase 
and blocked processive DNA synthesis, particularly at the low dNTP levels found in macrophages.
Conclusions: Taken together, these data provide strong mechanistic evidence that clofarabine is a dual action inhibi-
tor of HIV-1 replication that both limits dNTP substrates for viral DNA synthesis and directly inhibits the DNA polymer-
ase activity of HIV-1 reverse transcriptase.
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Background
Deoxyribonucleoside triphosphates (dNTPs) are essen-
tial for the genomic DNA replication of all organisms. 
In mammalian cells, two pathways supply the cell with 
dNTPs: the de novo synthesis pathway and the salvage 
pathway. Ribonucleotide reductase (RNR) is the rate-
limiting enzyme in de novo dNTP synthesis and acts 
by reducing ribonucleotides to deoxyribonucleotides. 
Nucleotide levels and cell cycle status tightly regulate the 
expression and activity of RNR [1, 2]. Prior to S phase, 
RNR activity greatly increases ensuring a sufficient sup-
ply of dNTPs for DNA replication. However, cells that are 
in nondividing or resting states display restricted RNR 
activity, which results in a low dNTP environment [3, 4]. 
In contrast, transformed/cancer cells, which are rapidly 
dividing with uncontrolled cell cycles, have significantly 
higher dNTP levels compared to normal dividing cells, 
and elevated dNTP levels are considered a biochemical 
marker for cancer cells [4, 5].
Various intracellular pathogens that synthesize DNA, 
including human immunodeficiency virus type 1 (HIV-
1), use cellular dNTPs for their genome replication. Two 
primary target cells of HIV-1 are activated CD4+ T cells 
and macrophages. Activated CD4+ T cells are dividing 
cells that contain abundant dNTPs (1–5 μM), synthesized 
by the highly expressed RNR, to support the replication 
of their genome [6–8]. On the other hand, macrophages 
are terminally differentiated and nondividing. Due in part 
to their extremely low RNR expression they have substan-
tially lower dNTPs (20–50 nM) than dividing cells [7–9]. 
HIV-1 replication kinetics is slower in macrophages 
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compared to activated CD4+ T cells [8, 10]. We previously 
reported that the low dNTP pools found in macrophages 
kinetically delays HIV-1 reverse transcription, suggest-
ing that limited dNTPs serve as a restriction mechanism 
against HIV-1 in nondividing cells [8].
Recently, SAM domain and HD domain containing 
protein 1 (SAMHD1) was identified as a potent myeloid-
specific host restriction factor of HIV-1 that depletes cel-
lular dNTPs [11], which subsequently suppresses HIV-1 
replication in nondividing cell types such as macrophages 
[12–14]. Interestingly, unlike HIV-1, HIV-2 and many 
SIVs encode a viral accessory protein, viral protein X 
(Vpx), that counteracts SAMHD1 and promotes retro-
viral replication in macrophages by elevating cellular 
dNTPs [13, 15, 16]. In addition to SAMHD1, other dNTP 
pool modulators have been shown to effect HIV reverse 
transcription. Most notably, cyclin-dependent kinase p21 
inhibits HIV replication by repressing the expression of 
an alternative RNR subunit called RNR2 [17]. Overall, 
these data indicate that sufficient dNTP levels are neces-
sary for viral reverse transcription and depleting dNTPs 
restricts viral replication.
Clofarabine is an FDA approved RNR inhibitor (RNRI) 
used in the treatment of acute lymphoblastic leukemia. 
As a purine nucleoside analog (Fig.  1a), clofarabine is 
transported into cells by nucleoside transporters and 
is phosphorylated by host enzymes to the active forms 
of the drug, clofarabine di- and triphosphate [18]. Both 
clofarabine di- and triphosphate inhibit RNR by binding 
the catalytic and the allosteric regulatory sites inducing 
hexamerization of the large subunit of RNR and subse-
quently preventing formation of the active enzyme. Due 
to the necessity of RNR in de novo dNTP synthesis, this 
inhibition causes a reduction in endogenous dNTPs, 
which in turn can inhibit DNA synthesis due to limited 
substrate availability [19, 20]. In addition to RNR inhi-
bition, clofarabine triphosphate (clofarabine-TP) can 
also be incorporated as an adenosine analog by DNA 
polymerase-α and -ε and can induce chain termination 
[21, 22]. Other DNA polymerases can also incorporate 
clofarabine albeit at a much-reduced rate that is not of 
biological significance. The mechanism for chain termi-
nation of clofarabine is not entirely clear; as clofarabine 
has a 3′ OH, it is not an obligate chain terminator like azi-
dothymidine (AZT). It has been observed that incorpora-
tion of clofarabine-TP reduces the rate at which the next 
nucleotide will be incorporated and incorporation of two 
consecutive clofarabine-TPs makes it extremely unlikely 
that the DNA chain will be further elongated. One cur-
rent hypothesis for this inhibition of extension is that the 
2′ fluorine atom may affect the reactivity of the 3′ OH 
and/or the quaternary structure of the DNA such that the 
polymerase fails to efficiently make the next bond [22].
We have previously demonstrated that clofarabine 
has anti-HIV activity in cell culture using a transformed 
cells line [23], however these studies did not examine the 
mechanism of action, or the anti-HIV activity and toxic-
ity in the primary target cells of HIV: activated CD4+ T 
cells and macrophages. Our biochemical and cell culture 
data indicate that clofarabine effectively blocks HIV-1 
replication by two distinct mechanisms: (1) reduction of 
cellular dNTPs and (2) direct incorporation by and inhi-
bition of HIV-1 reverse transcriptase, with very limited 
toxicity in macrophages.
Results and discussion
Anti‑HIV‑1 activity and cytotoxicity of clofarabine 
in human primary target cells
Clofarabine, a purine nucleoside analog (Fig.  1a) and 
RNRI, is an FDA approved anticancer compound that we 
have recently shown to have antiretroviral potency in a 
transformed cell line [23]. Here, we examined the anti-
HIV-1 activity of clofarabine in the primary human cells 
that are targets of HIV-1: activated CD4+ T cells and 
monocyte derived macrophages (MDMs). Cells were iso-
lated from five healthy donors, pretreated with varying 
concentrations of clofarabine for 8  h, and then infected 
with HIV-1 pseudotyped with vesicular stomatitis virus 
G protein (VSV-G). The construct used expresses the 
full-length HIV-1 genome, with a frameshift in env and 
two fluorescent protein genes, mCherry and enhanced 
GFP (EGFP), replacing a portion of rev and nef [24]. Cells 
were analyzed with flow cytometry at 5 days (MDMs) or 
3  days (T cells) after the addition of virus, and infected 
cells were determined by EGFP expression. Macrophages, 
as expected, showed a more restricted HIV-1 infection 
than the CD4+ T cells; however, however similar infectiv-
ity was achieved by using five times the amount of virus 
in MDMs (Additional file  1: Figure S1A). As shown in 
Figs. 1b and c (blue lines), clofarabine caused a concen-
tration-dependent decrease in HIV-1 infection in both 
cells types, with half maximal inhibitory concentration 
(IC50) values of 21.6 nM [95 % confidence interval (95 % 
CI) 17.4–25.8 nM] in macrophages and 60.3 nM (95 % CI 
24.1–96.5 nM) in activated CD4+ T cells. This three-fold 
increase in potency in macrophages compared to T cells 
is surprisingly minor—in the low dNTP environment of 
macrophages, we expected that the ratio of clofarabine-
DP and -TP to dADP and dATP, respectively, would be 
much higher than that found in T cells, and therefore 
considerably more potent. However, this analysis is com-
plicated by the fact clofarabine-TP has recently been 
identified as a substrate for SAMHD1, which is highly 
expressed in macrophages but not T cells [25].
We also determined the cytotoxicity of clofarabine 
in activated CD4+ T cells and macrophages (red lines 
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in Fig. 1b, c) using the XTT assay, and found that mac-
rophages are far more resistant to clofarabine-induced 
toxicity than activated CD4+ T cells, with CC50 values of 
6.8 μM (95 % CI 3.2–9.4 μM) and 854 nM (95 % CI 713–
996 nM), respectively. Additional toxicity assays, includ-
ing analysis of membrane integrity and cell size, were 
performed and supported this result (Additional file  1: 
Figure S1B–E).
This eight-fold difference in cytotoxicity indicates that 
macrophages are significantly more resistant to the toxic 
effects of clofarabine. The difference in clofarabine tox-
icity in macrophages and T cells may be due to multiple 
factors. One possibility is that T cells are actively divid-
ing which provides an opportunity for clofarabine-TP 
to be incorporated into their genome [26]. In cancer 
cells this genomic incorporation of clofarabine-TP has 
been show to be toxic. Additionally, nucleotide starva-
tion due to RNR inhibition and DNA damage response 
can induce cell cycle arrest and potentially lead to apop-
tosis [27–29]. These factors would not necessarily affect 
macrophages because they are nondividing state and 
therefore not replicating their genome and macrophage 
nucleotide levels are already extremely low compared to 
dividing cells. Another possible explanation is that clo-
farabine-TP, along with other dATP analogs, is known to 
induce mitochondrial toxicity by altering the mitochon-
drial transmembrane potential [30]. SAMHD1, which 
is highly expressed in macrophage but not T cells, may 
Fig. 1 Anti-HIV-1 activity of clofarabine in primary human activated CD4+ T cells and monocyte derived macrophages. a The structure of clofara-
bine. b Clofarabine inhibition (blue lines) and cytotoxicity (red lines) on activated CD4+ T cells of 5 healthy donors. Cells were treated with increasing 
concentrations of clofarabine for 8 h, washed with PBS, and then infected with pseudotyped HIV-1, (inhibition) or cultured with media (cytotoxicity). 
Analysis was conducted at 72 h post-infection via flow cytometry (inhibition) or XTT assay (cytotoxicity). The IC50 is 60.3 nM with a 95 % confidence 
interval (95 % CI) of 24.1–96.5 nM; the CC50 is 854.2 nM with a 95 % CI of 712.6–995.8 nM. c The clofarabine inhibition (blue lines) and cytotoxicity 
curves (red lines) for monocyte-derived macrophages of 5 healthy donors. Macrophages were treated as described for T cells except analysis was 
at 5 days post infection. IC50 = 21.6 nM (95 % CI 17.4–25.8 nM): CC50 = 6.8 μM (95 % CI 3.2–9.4 μM). d Selectivity Index (SI) difference between acti-
vated CD4+ T cells and macrophages. SI values were determined by dividing the average CC50 of five donors by the average IC50 of five donors
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be degrading clofarabine-TP and therefore limiting the 
effect of mitochondrial toxicity in MDMs.
Despite the fact that clofarabine-TP can be degraded 
by SAMHD1, clofarabine remains very potent in mac-
rophages (IC50 =  20.3  nM) and has limited cytotoxicity 
in this cell type. The selectivity index (SI, CC50/IC50) for 
clofarabine in macrophages is 314.8, 22-fold greater than 
the SI in activated CD4+ T cells (Fig. 1d), suggesting that 
clofarabine is a highly selective inhibitor of HIV-1 specifi-
cally in macrophages.
Effect of clofarabine on cellular dNTP levels and HIV‑1 DNA 
synthesis
We previously reported that the dNTP concentration in 
activated CD4+ T cells (1–5 μM) is above the Km value 
of HIV-1 RT (100–200 nM) [8, 31]. On the other hand, 
macrophages have low dNTPs (50  nM) with concen-
trations that are below the Km value of HIV-1 RT, sug-
gesting that the low dNTP levels kinetically delay HIV-1 
reverse transcription in macrophages [8]. Clofarabine 
is a known RNRI that can deplete endogenous dNTPs 
in transformed cell lines [21, 22]. Here, we wanted to 
investigate the extent to which clofarabine depleted 
endogenous dNTPs in activated CD4+ T cells and mac-
rophages. Specifically, we were interested in whether clo-
farabine would be effective in the extremely low dNTP 
environment in macrophages where RNR is not robustly 
expressed.
We pretreated both cell types, from three healthy 
donors with two different clofarabine concentrations, 
10 nM (below IC50 values for both cell types, Fig. 1b and 
c) or 300 nM (above IC50, but below CC50 values for both 
cell types), and methanol extracted the cellular dNTPs 
8  h later. To measure the cellular dNTP levels we uti-
lized a single nucleotide primer extension assay that we 
previously developed [8]. Briefly, this assay uses a 5′ P32 
radiolabelled 23-mer primer (P) annealed to one of four 
distinct 24-mer templates (T). The single nucleotide 
overhang on the 24-mer template (A, C, G or T) deter-
mines the dNTP to be measured. The template/primer 
was incubated with extracted cellular dNTPs and puri-
fied HIV-1 RT. The increase in radiolabelled 24-mer 
product indicates that the dNTP specific for the tem-
plate has been incorporated. In three donors, clofara-
bine induced at least 50 % reduction of dATP, dCTP and 
dGTP at 300 nM in activated CD4+ T cells (Fig. 2a) and 
macrophages (Fig. 2b). As with many RNRIs, dATP levels 
were the most affected by clofarabine-induced inhibition 
of RNR. This is possibly due to inefficient dATP synthesis 
via the salvage pathway, which does not involve RNR and 
is not affected by RNRIs [32–34]. Consistent with other 
reports, TTP levels were the least affected in both cell 
types possibly due to synthesis of TTP from dCMP and 
dUMP via the salvage pathway [21, 35]. One caveat of 
this assay is that clofarabine-TP is present in the cells and 
could be incorporated by HIV-1 RT. The predicted effect 
of clofarabine-TP incorporation would be an overesti-
mation in the amount of dATP calculated. Despite this 
potential problem, we saw a strong depletion of dATP in 
clofarabine-treated cells. This indicates that although the 
dATP levels may be overestimated we still observe effec-
tive RNR inhibition. We also measured the effect of clo-
farabine on dNTP levels in MAGI cells (a transformed 
cell line) using a mass spectrometry-based assay, which 
would be unaffected by clofarabine triphosphate, and saw 
a similar dNTP depletion profile to that seen in activated 
CD4+ T cells (Additional file 2: Figure S2A).
As shown in Fig.  2c, the dNTP concentrations in 
untreated macrophages (M) are already well below the 
Km of HIV-1 RT, and the clofarabine-induced dNTP 
reduction (M + clof ) would be expected to further delay 
HIV-1 reverse transcription and inhibit viral infection (as 
observed in Fig. 1c). However, the dATP concentration in 
activated CD4+ T cells (T) and in clofarabine-treated T 
cells (T + clof ) remains above the Km value of HIV-1 RT, 
suggesting that the clofarabine-induced dNTP reduction 
in T cells should not significantly affect HIV-1 reverse 
transcription kinetics. Despite this, we do see a reduc-
tion in pseudovirus infection in CD4+ T cells at 300 nM 
clofarabine treatment (Fig. 1b). One possible explanation 
is that the toxicity associated with clofarabine treatment 
may be responsible for the decrease in infection; however, 
we see potent anti-HIV-1 activity at levels that are not 
toxic, making this unlikely. Another possibility is it that 
clofarabine may be acting through an additional mecha-
nism that is not directly related to its RNR inhibition.
Next, we confirmed that the observed clofarabine-
induced HIV-1 inhibition (blue lines in Fig. 1b, c) is due 
to the inhibition of HIV-1 DNA synthesis by employ-
ing quantitative PCR to measure a reverse transcription 
product. Clofarabine treatment led to a decrease in viral 
DNA synthesis that correlated with a decrease in infec-
tion (Fig. 2d). These results are similar to those seen with 
AZT, a known chain terminator. In contrast, the inte-
grase inhibitor raltegravir (Ralt) decreased infectivity by 
approximately 80  %, but this loss did not correlate to a 
reduction in viral DNA synthesis. These results indicate 
that clofarabine reduces reverse transcriptase-mediated 
viral DNA synthesis through, at least in part, its inhibi-
tion of RNR, which deplete endogenous dNTPs.
Incorporation of clofarabine‑TP by reverse transcriptase
Our activated CD4+ T cell data indicated that the 
clofarabine-induced dNTP depletion would still pro-
vide a kinetically favorable environment for reverse 
transcription. It has been reported that clofarabine 
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triphosphate (clofarabine-TP) is efficiently incorpo-
rated into DNA by DNA polymerase α and ε as a dATP 
analog [21, 22]. Therefore, we tested whether HIV-1 RT 
can directly incorporate clofarabine-TP into DNA. For 
this test, clofarabine-TP and purified HIV-1 RT were 
incubated with a 5′ 32P-labeled 23-mer DNA primer (P) 
annealed to a 24-mer DNA template containing a sin-
gle T overhang, which allows RT to incorporate a single 
clofarabine-TP. As shown in Fig.  3a, a 24-mer extended 
product (E) was observed in the presence of clofarabine-
TP at concentrations as low as 50  nM and the amount 
of 24-mer produced increased with increasing concen-
trations of clofarabine-TP. These results demonstrate 
that clofarabine-TP is a substrate for HIV-1 reverse 
transcriptase. HIV-1 RT is known for its high error rate 
and low fidelity [36, 37], raising the possibility that clo-
farabine could act as a general purine nucleoside analog. 
Therefore, we also tested whether clofarabine could 
be incorporated as a dGTP analog by using a “C” over-
hang template/primer. In this assay, we did not observe 
any clofarabine-TP incorporation by HIV-1 RT (data 
not shown), indicating that clofarabine-TP is incorpo-
rated only as a dATP analog, not as a nonspecific purine 
analog.
Next, we investigated whether the incorporation of 
clofarabine-TP by HIV-1 RT inhibits primer extension. 
Fig. 2 Clofarabine induced depletion of cellular dNTPs and inhibition of reverse transcription. Effect of clofarabine on cellular dNTP levels in 
primary activated CD4+ T cells (a) and macrophages (b) from three healthy donors. Activated CD4+ T cells and macrophages were treated with the 
indicated concentration of clofarabine for 8 h, washed with PBS, and dNTPs were extracted for analysis. dNTP levels are expressed as a percentage 
of the vehicle control (DMSO). Each value represents an individual donor with mean ± SD indicated. *p < .05 compared to vehicle control (multiple 
t test with Holm-Sidak post hoc test). c Cellular dATP concentrations of untreated and clofarabine (300 nM) treated T cells and macrophages from 
three healthy donors. Measured dATP levels were converted to cellular dATP concentrations as previously described [8], and are expressed as 
mean ± SD). Blue bar indicates the Km range of HIV-1 RT [8, 31]. T: untreated T cells, T + clof: T cells + 300 nM clofarabine, M: untreated mac-
rophages, M + clof: macrophages + 300 nM clofarabine. d Clofarabine effect on HIV-1 proviral DNA synthesis. MAGI cells were incubated with 
DMSO (NI, HI, ND), 200 nM AZT, 300 nM clofarabine (Clof ), or 50 nM raltegravir (Ralt) for 2 h prior to infection with pseudotyped HIV-1. Infection 
(black bars) was determined at 48 h post-infection, and reverse transcription (grey bars) efficiency was determined at 18 h post-infection. Data 
represent mean ± SD from three independent experiments and are expressed as percentage of vehicle control (DMSO, 100 %). NI no infection, HI 
heat inactivated virus, ND no drug
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For this experiment, reactions contained 5′ 32P-labeled 
17-mer primer (P) annealed to a 38-mer RNA template 
(sequence indicated below, Fig.  3 B/D in box), dNTPs 
(at either the concentrations found in activated T cells, 
5  μM, or macrophages, 50  nM), increasing concentra-
tions of clofarabine-TP, and excess HIV-1 RT. As shown 
in Fig. 3b, when the primer was extended by HIV-1 RT at 
the T cell dNTP concentrations (5 μM), pausing of DNA 
synthesis (* in Fig. 3b) was observed only at the highest 
dose of clofarabine-TP (125  nM). However, at the mac-
rophage dNTP concentrations (50  nM), the RT pausing 
was observed at much lower clofarabine-TP concen-
trations, and the full-length extension was completely 
inhibited at the highest clofarabine-TP concentration 
(125  nM). As expected, a stall site was observed across 
from a U site in the template (* in Fig.  3b) indicating 
that clofarabine-TP was incorporated as an adenosine 
analog. More interestingly, this stall induced inefficient 
Fig. 3 Biochemical examination of the dual mechanism of clofarabine. a Direct clofarabine-TP incorporation by HIV-1 RT. A 5′ 32P-labeled 23-mer 
DNA primer (P) annealed to a 24-mer DNA template with a single T overhang was incubated with HIV-1 RT and increasing concentrations of clofar-
abine-triphosphate (Clof-TP). E, Extended product; +, 50 μM dATP positive control; −, no dATP control. b Effect of clofarabine-TP incorporation on 
DNA synthesis. A 5′ 32P-labeled 17-mer DNA primer (P) annealed to a 38-mer RNA template was extended by HIV-1 RT with fixed dNTP concentra-
tions found in either activated T cells (T cell, 5 μM) or monocyte-derived macrophages (MDM, 50 nM) with increasing concentrations of clofarabine-
TP (two-fold dilutions starting at 125 μM). F, Fully extended product; +, 50 μM dNTP positive control; −, no dNTP control. Blue asterisks (*) indicates 
the clofarabine-TP incorporation site followed by kinetic pauses (]). c Clofarabine inhibition of NRTI-resistant RT mutants. MAGI cells were treated 
with increasing concentrations of clofarabine for 2 h prior to infection with Vsvg-pseudotyped HIV-1 containing mutations in RT. Flow cytometry 
analysis for infected cells was conducted at 48–72 h post-infection. IC50 values and 95 % confidence intervals are shown. NL4-3 MIG: wild-type HIV-1 
RT, Q151: A62V, V75I, F77L, F116Y and Q151M, T69: M41L, A62V, T69S, K70R, T215Y and serine–serine insertion between 69 and 70. d Biochemical 
simulation of HIV-1 RT activity at dNTP concentrations found in cells with and without clofarabine treatment. A 5′ 32P-labeled 17-mer DNA primer 
(P) annealed to a 38-mer RNA template (shown in box) was extended using an equal amount of purified HIV-1 RT protein with dNTP concentrations 
found in T cells (T, 5 μM), macrophages (M, 50 nM) or macrophages treated with 300 nM clofarabine (M/C, 10 nM dATP, 28 nM dCTP, 28 nM dGTP, 
40 nM TTP). Blue stars (*) indicate kinetic pause sites, F, fully extended 38 bp product; −, no dNTP control
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subsequent dNTP incorporation (] in Fig. 3b), causing RT 
pausing and eventually blocking full length DNA synthe-
sis. These data indicate that HIV-1 RT can directly incor-
porate clofarabine-TP and that its incorporation inhibits 
processive viral DNA synthesis, particularly at the low 
dNTP environment found in non-dividing macrophages.
There are numerous mutations in RT that render HIV-1 
resistant to NRTIs, many of which confer multi-drug 
resistance. To determine whether these mutations would 
also confer resistance to clofarabine, we treated MAGI 
cells with increasing amounts of clofarabine for 2 h prior 
to infection with pseudotyped HIV-1 vectors containing a 
panel of known RT mutations [38]. As shown in Fig. 3C, 
clofarabine had similar potency against the NRTI-resistant 
RT mutants as against wild type (NL4-3 MIG). This data 
could indicate that the primary mechanism of HIV-1 inhi-
bition is RNR inhibition rather than incorporation by RT. 
However, many mutations in RT that confer resistance to 
individual NRTIs have no effect on different NRTIs, and 
some can increase susceptibility to certain drugs. Inter-
estingly, clofarabine’s structure is very different from all 
FDA-approved NRTIs because it has a 3′OH and is not an 
obligate chain terminator. It is possible that the potency of 
clofarabine against known NRTI-resistant RTs is due to its 
differential chemical structure and that clofarabine may 
work via both mechanisms: RT and RNR inhibition. Selec-
tion experiments to develop a clofarabine-resistant strain 
are planned to further explore this question.
In order to separate the two distinct mechanisms of 
clofarabine, reduction of dNTPs and direct inhibition 
of DNA synthesis via incorporation, we biochemically 
compared the DNA synthesis efficiency of HIV-1 RT at 
the cellular dNTP concentrations described in Fig.  2c. 
For this, we extended a 5′ 32P-labeled 17-mer primer (P) 
annealed to a 38-mer RNA template (sequence indicated 
in box below Fig.  3b/d) with an equal amount of puri-
fied HIV-1 RT protein at three different dNTP concen-
trations: that found in T cells (T, 5 μM), in macrophages 
(M, 50  nM) and in macrophages that had been treated 
with 300  nM clofarabine (M/C, Fig.  3d). This experi-
ment was conducted in the absence of clofarabine so 
that we could observe the effect of clofarabine induced 
dNTP reduction on DNA synthesis in the absence of any 
effects of clofarabine incorporation. As shown in Fig. 3d, 
HIV-1 RT generated the fully extended product (F) at T 
cell dNTP concentrations, whereas HIV-1 RT displayed 
limited primer extension with clear kinetic pausing (*) in 
the macrophage simulated dNTP concentrations. This 
RT-pausing was further enhanced at the dNTP concen-
trations observed in clofarabine treated macrophages, 
which ranged from 10 to 40  nM (Fig.  3d). These data 
recapitulate previous data indicating that the dNTP 
pools in macrophages have a restrictive effect on reverse 
transcription [8, 14] and support our hypothesis that a 
further reduction in dNTPs will lead to a corresponding 
decrease in HIV-1 viral DNA synthesis. From these bio-
chemical analyses, we suggest that clofarabine induced 
dNTP depletion in macrophages reduces reverse tran-
scription (Fig.  3d) while also increasing the likelihood 
of direct incorporation of clofarabine-TP during reverse 
transcription, which in turn can cause inhibition of pro-
cessive DNA synthesis (Fig. 3b).
As summarized in Fig.  4, we report that clofarabine, 
which is converted to clofarabine-DP and clofarabine-
TP in cells, can inhibit HIV-1 reverse transcription 
by two distinct mechanisms: (1) reduction of cellular 
dNTPs through the inhibition of RNR (by clofarabine-
DP and clofarabine-TP) and (2) direct incorporation of 
clofarabine-TP by HIV-1 RT and inhibition of viral DNA 
synthesis. Importantly, the inhibitory impact of clofara-
bine imposed by these two mechanisms becomes more 
effective in non-dividing macrophages because this 
viral target cell type is less sensitive to the toxic effects 
of clofarabine. In addition, macrophages maintain lim-
ited dNTP pools, in part due to the dNTPase activity of 
host protein SAMHD1. Interestingly, many nucleoside 
analogs are not substrates for SAMHD1, which increases 
nucleoside reverse transcriptase inhibitor (NRTI) effi-
cacy in macrophages [39]; however, it was recently pub-
lished that clofarabine-TP is degraded by SAMHD1 
in  vitro [25]. Despite this, clofarabine was still able to 
Fig. 4 Model for the anti-HIV-1 dual action mechanisms of clofara-
bine in macrophages. Clofarabine di- and triphosphate inhibit RNR 
to reduce dNTP levels, leading to the kinetic suppression of HIV-1 
reverse transcription (blue). Clofarabine triphosphate is also directly 
incorporated by HIV-1 RT, inhibiting extension (red)
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reduce dNTPs and restrict viral replication efficiently in 
macrophages.
Our previous publication reported that clofarabine is 
threefold more effective against HIV-2 than HIV-1 [23]. 
This result is surprising in light of our current report 
that clofarabine exerts its antiviral effect at least in part 
through reducing dNTP levels: the HIV-2 protein Vpx 
counteracts SAMHD1 and promotes retroviral replication 
in macrophages by elevating cellular dNTPs, and there-
fore would be expected to be more resistant to clofarabine 
than HIV-1, which does not contain Vpx. However, the 
previous work on HIV-2 was performed in U373-MAGI-
CXCR4CEM cells, a transformed cell line derived from a 
human glioblastoma, which have very limited SAMHD1 
expression, abundant dNTPs and are highly permis-
sive to HIV-1 infection. This indicates that the difference 
seen between HIV-1 and HIV-2 inhibition by clofarabine 
in the previous report is likely not Vpx or dNTP related 
but more likely related to differences in RT fidelity. Com-
paring the effect of clofarabine on HIV-1 and HIV-2 in 
primary human macrophages would be interesting, but 
we believe it would be difficult to explain the outcome 
mechanistically due to the SAMHD1-mediated hydroly-
sis of clofarabine-TP (31). Degradation of SAMHD1 by 
Vpx would lead to an increase in both dNTP and clofar-
abine-TP levels complicating the expected experimen-
tal outcome of the potency of clofarabine. A dual RNRI/
NRTI that is resistant to SAMHD1 hydrolysis would 
be expected to have significantly higher efficacy against 
HIV-1 than does clofarabine, and would be a much better 
tool to study the effects of Vpx on RNR inhibition.
Any suggestion of using an RNRI as a clinical treatment 
for HIV-1 runs into the specter of hydroxyurea, an RNRI 
which failed clinically as an anti-HIV drug due primarily 
to its accentuation of NRTI toxicity [40]. Given the self-
potentiation inherent to clofarabine’s dual mechanisms 
of action, potentiation of toxicity would be a serious risk; 
however, there are significant differences between the 
two RNRIs. Hydroxyurea and clofarabine differ greatly in 
structure and in the mechanism of RNR inhibition. Clo-
farabine has been used as a second line cancer treatment 
since its FDA approval in 2004 and recent trials have had 
positive results using it as a first line cancer treatment 
that can be administered orally [41, 42]. Any use of clo-
farabine as an HIV drug would require further drug inter-
action studies to establish the safety of clofarabine both 
alone and with commonly used combination therapies. 
The current study was designed to study the mechanism 
of action and toxicity of clofarabine as a model for dual 
RNR/HIV-1 RT inhibitors in primary human target cells. 
We propose that clofarabine be used as a base molecule 
for further drug design studies. A derivative that shows 
resistance to SAMHD1 hydrolysis while maintaining the 
activity and low toxicity of clofarabine in macrophages 
would be of great interest. This would increase drug 
efficacy by reducing the natural dNTP competition 
and ensure that drug concentrations remain high for 
increased incorporation. In conclusion, our experimental 
observations of cellular dNTP level reduction by clofara-
bine (below Km value of HIV-1 RT) and more effective 
incorporation of clofarabine-TP at these lowered dNTP 
concentrations support that clofarabine can be a model 
agent for dual function anti-HIV agents.
Methods
Cell lines, plasmids, and chemicals
The 293T cell line was obtained from the American Type 
Culture Collection (Manassas, VA) while U373-MAGI-
CXCR4CEM (MAGI) cells were obtained from Dr. Michael 
Emerman through the AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH [43, 
44]. The HIV plasmid pNL4-3 MIG has been previously 
described [24]. RT resistant mutants were created as pre-
viously described [38] and subcloned into pNL4-3 MIG. 
The VSV-G envelope plasmid, pHCMV-VSVG, was pro-
vided by J. Burns (University of California, San Diego). 
Clofarabine was purchased from Carbosynth (Berkshire, 
UK). The following reagents were obtained from the NIH 
AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
Raltegravir (Cat # 11680) from Merck & Company, Inc. 
and zidovudine.
Cell culture
293T and MAGI  cells were maintained as previously 
described [45]. Primary human monocytes and CD4+ T 
cells were isolated from peripheral blood buffy coats by 
positive selection using CD14 or CD4 beads (Miltenyi 
Biotec, San Diego, CA), as previously described [46], and 
maintained in RPMI medium with 10  % FCS and peni-
cillin/streptomycin. CD14+ monocytes were matured to 
macrophages using 5 ng/mL human GM-CSF for 7 days 
(Miltenyi Biotec). CD4+ T cells were activated with 5 µg/
mL phytohemagglutinin (Sigma-Aldrich) and 20 units/
mL IL2 (Miltenyi Biotec) for 1 day, then 20 units/mL IL2 
alone for 5 days.
Production of viral stocks
293T cells were co-transfected with pNL4-3 MIG and 
pHCMV-VSVG using linear polyethylenimine from Poly-
sciences, Inc. (Warrington, PA) as previously described 
[47]. Virus was harvested at 48 and 72 h post-transfection 
and used immediately or frozen at −80 °C.
Drug treatments and infections
MAGI cells were infected as described previously [45]. 
Cells were treated with clofarabine for 2  h prior to 
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infection with viral supernatant. Cells were harvested 
for analysis 48–72 h after infection and analyzed with a 
BD Biosciences LSRII flow cytometer. Vehicle treated 
cells had 15–35  % infection. Primary cells were treated 
with clofarabine for 8 h, washed twice with PBS and then 
infected with viral supernatant. To achieve the same infec-
tivity, MDMs were infected with five times the amount of 
viral supernatant than T cells. Monocyte derived mac-
rophages (MDM) were collected 5 days post-infection and 
activated CD4+ T cells were collected 3 days post-infec-
tion for analysis via flow cytometry. Data analysis was 
performed using FloJo and Prism 6. IC50 and CC50 were 
determined using GraphPad Prism nonlinear fit analyses; 
log (inhibitor) versus response–variable slope.
Cell proliferation and cytotoxicity
MDMs and T cells were treated with clofarabine for 
8 h, washed twice with PBS and maintained in media 5 
or 3 days, respectively (same treatment as infection pro-
tocol). The XTT assay from ATCC was used as per the 
manufacturer’s protocol. The optimized assay incubation 
time for both cell types was 5 h. For additional measures 
of toxicity, including trypan blue exclusion and cell size, 
cells were treated the same as above and analyzed using 
the Vi-Cell Counter (Beckman Coulter).
Real‑time qPCR of RT products
Real time qPCR was performed essentially as previously 
described [48]. MAGI cells (150,000 per well) were plated 
on a six-well plate. Twenty-four hours later, cells were 
treated with the indicated drug for 2 h prior to infection. 
As a control, an aliquot of virus was heat inactivated for 
30 min at 95 °C. Eighteen hours after infection, cells were 
harvested with trypsin; half were re-plated for the analysis 
of infection, and DNA was isolated from remaining cells 
using HighPure PCR Template Preparation Kit (Roche, 
Basel, Switzerland). Quantitative PCR (qPCR) mixtures 
contained 4 μL of eluted DNA using iTaq Universal SYBR 
Green Supermix according to the manufacturer’s sugges-
tions (BioRad, Hercules, CA). Primers for 18S rRNA were 
used to normalize sample-to-sample variation. The prim-
ers used to detect late reverse transcription (RT) prod-
ucts were 5′TGTGTGCCCGTCTGTTGTGT (forward) 
and 5′GAGTCCTGCGTCGAGAGAGC (reverse). The 
primers used to detects 18S rRNA were 5′GTAACCC 
GTTGAACCCCATT (forward) and 5′CCATCCAATCGG 
TAGTAGGG (reverse). The conditions for amplification 
were 95 °C for 10 min, followed by 40 cycles of 95 °C for 
30 s, 60 °C for 30 s, and 72 °C for 30 s.
Synthesis of clofarabine triphosphate
Clofarabine triphosphate was synthesized as previously 
described [49] with minor modifications. In separate 
round-bottom flasks, clofarabine (0.1  g, 1.0  eq.) and 
tributylammonium pyrophosphate (0.361  g, 2.0  eq.) 
were dried under high vacuum for 1  h at ambient tem-
perature. Throughout the entire experiment, the reaction 
was maintained under an argon atmosphere. Clofara-
bine (0.1 g, 1.0 eq.) was dissolved in anhydrous dioxane 
(0.9  mL, 3  mL/mmol) and anhydrous pyridine (0.3  mL, 
1  mL/mmol). The flask was cooled with an ice bath. A 
solution of 2-chloro-4H-1,3,2- benzodioxaphosphorin-
4-one (80  mg, 1.2  eq.) in anhydrous dioxane (0.4  mL, 
1  mL/mmol) was added and the mixture was then 
stirred at room temperature for 15  min. A solution of 
tributylammonium pyrophosphate (361  mg, 2.0  eq.) 
in anhydrous DMF (0.7  mL, 1  mL/mmol) was added to 
the mixture, prior to quick addition of tributylamine 
(0.4 mL, 5.0 equiv). The mixture was stirred for 15 min 
at room temperature. A solution of iodine (1 % solution 
in pyridine/water, 9:1) was then added dropwise until 
the permanent brown color of iodine persisted, and the 
mixture was stirred for 20 min. The excess of iodine was 
quenched with a 5  % aqueous solution of Na2S2O3. The 
reaction mixture was evaporated to dryness under vac-
uum, dissolved in 25 % ammonia solution, and stirred for 
1  h at room temperature. The reaction was monitored 
by TLC (Rf 0.1 isopropanol/aqueous ammonia  =  1/1 
and MS). The reaction mixture was concentrated under 
reduced pressure and resulting crude product was puri-
fied on a short pad of silica gel with a gradient of isopro-
panol/aqueous ammonia 8/2 to 1/1 affording the desired 
5′-triphosphate ammonium salt, 21  % yield (75  % pure 
with diphosphate as an impurity, determined by 31P 
NMR). The synthesized nucleoside 5′-triphosphate was 
confirmed by 1H NMR, 31P NMR, and HR-MS analyses 
consistent with published analytical data for clofarabine 
5′-triphosphate [19].
HIV‑1 RT purification
HIV-1 (NL4-3) RT homodimer with a hexahistidine tag 
was expressed using an overexpression system in BL21 
E. coli [50, 51], and purified using Ni2+ chelation chroma-
tography as described previously [8, 51].
dNTP quantification
dNTPs from primary cells were extracted and quanti-
fied using the protocol previously described by Diamond 
et  al. [8]. Briefly, this assay uses a 5′ P32 radiolabelled 
23-mer primer (P) annealed to one of four distinct 
24-mer templates (T). The single nucleotide overhang on 
the 24-mer template (A, C, G or T) determines the dNTP 
to be measured. The template/primer was incubated 
with extracted cellular dNTPs and purified HIV-1 RT 
for 5 min at 37° and then quenched with 40 mM EDTA 
and 99  % (vol/vol) formamide at 95  °C for 2  min. The 
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reactions were resolved on a 20 % urea-PAGE gel (Ameri-
can Bio Sequel NE reagent) and imaged using Pharos FX 
molecular imager (Biorad). The increase in radiolabelled 
24-mer product indicates that the dNTP specific for the 
template has been incorporated. MAGI cells were treated 
with 100 or 300 nM clofarabine for 8 h, then harvested, 
counted, resuspended in 60  % methanol, and stored at 
−20 °C for 18 h. Samples were then vortexed, heated to 
95  °C for 3 min, and centrifuged at 16,000×g for 5 min. 
Supernatant was transferred to new tubes and dried in 
an Eppendorf Vacufuge. Samples were then stored at 
−80 °C.
To perform LC–MS/MS analysis, dried extracts were 
reconstituted in water at a concentration of 1 million 
cells per 100 µL. For each reconstituted sample, a 50 µL 
aliquot of resuspension was added to an Eppendorf tube 
containing 50  µL of internal standard (10  µM 5-iodo-
dCTP in water), and then diluted with 100  µL water. 
The samples were then centrifuged at 14,000  rpm for 
5  min at 4  °C. LC–MS/MS was used to determine lev-
els of TTP, dGTP, dCTP and dATP in the supernatants 
following a previous published method [52] with minor 
modifications. The LC–MS/MS system consists of an 
AB Sciex QTrap 5500 mass spectrometer and an Agi-
lent 1260 Infinity HPLC. The chromatographic separa-
tion of analytes was achieved using a Thermo Scientific 
Hypercarb column (100 × 3 mm, 5 µm). The two eluents 
were: (A) 0.5 % diethylamine in water, pH adjusted to 10 
with acetic acid; and (B) 50 % acetonitrile in water. The 
mobile phase was delivered at a flow rate of 0.5 mL/min 
using stepwise gradients of A and B: 0–20 min, 0–25 % B 
(v/v); 20–28 min, 25–50 % B (v/v); 28–28.5 min, 50–95 % 
B (v/v); 28.5–30.5  min, 95–95  % B (v/v); 30.5–31  min, 
95–0  % B, (v/v); 31–39  min, 0–0  % B (v/v). Only eluate 
from 10-30 min was diverted into the mass spectrometer 
for analysis. MS/MS detection of the analytes was con-
ducted using an ESI ion source with MRM detection in 
negative mode. The curtain gas was set at 20 psi. The ion-
spray voltage was set at −4500 V, and the temperature at 
650 °C. The nebulizer gas (GS1) and turbo gas (GS2) were 
both set at 45 psi.
In vitro clofarabine triphosphate incorporation assay
This single nucleotide extension assay was modified 
from a previously described assay [51]. A 5′ 32P-labeled 
DNA 18-mer (5′-GTCCCTCTTCGGGCGCCA-3′) was 
annealed to a 19-mer DNA template (3′-CAGGGAGA-
AGCCCGCGGTG-5′) at a 1:2 ratio. Extension from an 
18-mer to 19-mer indicates that clofarabine triphosphate 
has been incorporated by HIV-1 reverse transcriptase. 
20  μL reactions contained 200 fmol template/primer, 
2  μL clofarabine triphosphate at concentrations indi-
cated or 50 μM of dNTPs for the positive control, 4 μL 
of purified RT (HIV-1 NL4-3), 25 mM Tris–HCl, pH 8.0, 
2  mM dithiothreitol, 100  mM KCl, 5  mM MgCl2, and 
10 µM oligo(dT). Reactions were incubated at 37  °C for 
5  min and then quenched with 10  µL of 40  mM EDTA 
and 99  % (vol/vol) formamide at 95  °C for 2  min. The 
reactions were resolved on a 20 % urea-PAGE gel (Ameri-
can Bio Sequel NE reagent) and imaged using Pharos FX 
molecular imager (Biorad).
Primer extension assay
An HIV-1 RT primer extension assay was performed as 
previously described with slight modifications [53]. A 5′ 
32P-labeled 17-mer DNA primer (5′-CGCGCCGAATTC-
CCGCT-3′) was annealed to a 40-mer RNA template 
(5′-AAGCUUGGCUGCAGAAUAUUGCUAGCGG-
GAAUUCGGCGCG-3′) in the presence of 100  mM 
NaCl, 10 mM Tris–HCl (pH 8.0) and 1 mM EDTA. 20 µL 
Reaction mixtures contained 10  nM template-primer, 
4  µL of purified HIV-1 RT, 5  µM or 50  nM of all four 
dNTPs (ThermoScientific), 12.5 mM Tris–HCl (pH 7.5), 
12.5  mM NaCl, 2.5  mM MgCl2 and 20  µM oligo(dT). 
Reactions were initiated upon addition of RT and incu-
bated at 37 °C for 1 h (for Fig. 3b) and 5 min (for Fig. 3d). 
Reactions were terminated with 10 µL of 40 mM EDTA, 
99  % formamide and the products were resolved on a 
14  % urea-PAGE gel (American Bio Sequel NE reagent) 
and imaged using Pharos FX molecular imager (Biorad) 
and analyzed using ImageLab software.
Additional files
 Additional file 1: Figure S1. Infectivity and toxicity in T cells and 
macrophages. (A) Activated CD4+ T cells and macrophages were infected 
with pseudotyped HIV-1. In order to achieve similar levels of infection 
more pseudovirus was used to infect macrophages (5X more virus used). 
Individual donor infectivity is shown with technical triplicates shown as 
standard error (mean with standard deviation). (B) Cell viability in acti-
vated CD4+ T cells. Cells were treated with varying amounts of clofarabine 
for 8 h, washed in PBS and maintained in media for 72 h. Cell viability was 
determined by exclusion of trypan blue indicating membrane integrity 
by the Vi-cell counter. (C) Cell size of activated CD4+ T cells treated with 
clofarabine. Cells were treated with varying amounts of clofarabine for 
8 h, washed in PBS and maintained in media for 72 h. Cells were counted 
and cell size was determined using the Vi-Cell counter. (D) Cell viability in 
macrophages. Cells were treated with varying amounts of clofarabine for 
8 h, washed in PBS and maintained in media for 5 days. Cell viability was 
determined by exclusion of trypan blue indicating membrane integrity 
by the Vi-cell counter. (E) Cell size of activated CD4+ T cells treated with 
clofarabine. Cells were treated with varying amounts of clofarabine for 8 h, 
washed in PBS and maintained in media for 5 days. Cells were counted 
and cell size was determined using the Vi-Cell counter.
Additional file 2: Figure S2. Clofarabine induced depletion of cellular 
dNTPs in MAGI cells. MAGI cells were treated with 100 nM (~IC50) and 
300 nM (~IC90) clofarabine for eight hours, washed with PBS, and dNTPs 
were methanol extracted and analyzed by LC–MS/MS. Data shown repre-
sents mean ± SD of three independent experiments, and is expressed as 
a percentage of vehicle control. * = p < .05 compared to vehicle control 
(multiple t test with Holm-Sidak post hoc test).
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